Previous 10 |
naphtalina/iStock via Getty Images Day One Biopharmaceuticals ([[DAWN]] +1.8%) has lost ~16.0% in value since its public debut in late May. Today as its IPO quiet period draws to a close, the clinical-stage biopharma company has attracted a range of bullish recommendations from Wall Street. T...
SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced that the European C...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Big Tech will be in the spotlight next with the U.S. House Judiciary Committee expected to vote on a package on antitrus...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Despite a ~61.8% gain on public debut, Day One Biopharmaceuticals ([[DAWN]] -17.3%) is one course to record a sharp one-day loss after reaching a session low today.The company remained ~38.6% higher through yesterday after pricing the IPO at $16.00 apiece at the top of an expected $14.00...
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announce...
News, Short Squeeze, Breakout and More Instantly...
Day One Biopharmaceuticals Inc. Company Name:
DAWN Stock Symbol:
NASDAQ Market:
Day One Biopharmaceuticals Inc. Website:
2024-07-20 21:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-10 18:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 09:30:06 ET Piper Sandler analyst issues OVERWEIGHT recommendation for DAWN on July 8, 2024 07:54AM ET. The previous analyst recommendation was Overweight. DAWN was trading at $13.71 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...